The combination therapy group had greater reductions in systolic blood pressure and diastolic BP compared with semaglutide and cagrilintide
Foundational NNMT Discoveries The foundational research establishing NNMT as a metabolic regulator and potential therapeutic target came from studies by Daniel Kraus and colleagues published in Nature in 2014, which demonstrated that NNMT expression is dramatically upregulated in adipose tissue of obese humans and diet-induced obese mice, and that genetic knockdown of NNMT in mice protected against diet-induced obesity and improved metabolic parameters
Although peptide therapy is often promoted for its targeted approach, it still requires medical oversight
Nicola A, Petiot N, Grassein P, Delarue P, Neiers F, Senet P
Delwing-de Lima D, Ulbricht ASSF, Werlang-Coelho C, Delwing-Dal Magro D, Joaquim VHA, Salamaia EM, et al